Cougar Biotechnology, Inc.

CB7630 phase I data presented at Prostate Cancer Foundation scientific retreat

Published in Law and Health Weekly, November 27th, 2004

Cougar Biotechnology, Inc., a privately held biotechnology company, announced that results from the phase I clinical trials of Cougar's investigational drug, CB7630 (abiraterone acetate), were presented at the Prostate Cancer Foundation scientific retreat on October 23, 2004.

The phase I trials of CB7630 were conducted at the Cancer Research UK Centre for Cancer Therapeutics/Institute of Cancer Research and the Royal Marsden Hospital in the United Kingdom, and the results were published in the British Journal of Cancer in June, 2004.

The presentation, entitled "CB7630 (Abiraterone Acetate): A Novel Targeted Oral Therapy for Hormone-Refractory...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2004-11-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry